legato-hd phase 2: a clinical trial update
TRANSCRIPT
vsLAQUINIMOD
A clinical trial update
Phase 2
HUNTINGTONS
In the red corner,the undefeatedHUNTINGTONS
In the blue corner,the new-hopeful
LAQUINIMOD
How will itfight HD?
Laquinomid canchange the activity of
our immune system.
Normally, this helps us fight diseases by
stimulating inflammation.
But, in neurodegenerative diseases too much inflammation might
be a problem...
By slowing down the immune system
laquinomid could slow the progress of Huntingtons.
How do we know this?
By studying another diseasecalled Relapse-Remitting
Multiple Sclerosis...
A disease which getsworse, then betterthen even worseas it advances.
When it gets worse: too much inflammation
is the problem.
Laquinimod is being tested against this disease in
another trial calledConcerto...
Which is already in stage 3.
This experience fighting MSis good preparation for
its fight against Huntingtons.
It gives us crucial information about how it will behave in the ring - our bodies!
(There’s no point supporting laquinimod if it’s going
to do us harm)
What information have we learned about
Laquinimod?
We have learned:How much our bodies
can handle - a safe dose.
Also:What problems our bodies
could have - the side-effects.
This information means the HD-trial has started
in a strong position.
Legato-HD is now on phase 2.
Whats the aim of Phase 2?
To continue checking safety- to see what can we
consume on a daily basis.
To start testing efficacy- to see if it has an
effect on Huntingtons.
How will we know if it has?
By measuring Motor-score: a sign of how well a patient can control their movement.
If this score declines less in patients taking the drug,
Laquinimod is helping!
This is the studies primary end-point:
the trial will only continue if this improves after 12 months.
So, whats the story so far?
By June 2016400 adults - with
and without HD - were meant to be recruited.
They were to receivea daily dose of either:
a placebo, 0.5 mg, 1.0 mg, 1.5 mg.
In Jan 2016,it was decided to stop the 1.5 mg daily dose.
This was because of a recomendation from the
MS study, Concerto...
Some of their patients ona similar 1.2mg dose had heart problems.
As a result, no one new is being recruited to
to take the highest dose.
But, the other 2 doses and placebo are
still running.
The bad news:The recruitment deadline has been pushed back
(delaying the study)
The good news:They will now only need to
recruit 300 patients (one dose is missing)
Conclusion?
In a heavy-weight fight,information like this is
exactly what we need if...
We want to improve the odds of a win for
Laquinimod!
A visualscience presentation made by @DeLaSouz
for HDYO